drug
LEQEMBI
updated 6mo agoby Eisai Co Ltd
community read0 votes
🐶 often sniffed alongside
top 2all catalysts(0)
nothing on the calendar yet
News(10)
- Biogen inks $411M neurodegeneration pact with protein degrader biotech TrimTechCambridge, U.K.-based TrimTech Therapeutics has linked up with Biogen in a collaboration worth up to $411 million in biobucks to develop protein degraders for neurodegenerative diseases.fiercebiotech · 1d ago
- Alzheimer’s field looks beyond amyloid as biopharma converges at CTAD 2026This week, biopharma companies including Biogen, Bristol Myers Squibb and Roche are in Boston with new data on their efforts to tackle Alzheimer’s disease.biospace · 1d ago
- London biotech Oyster harvests $60M for tau-targeting brain drugsOyster says a tweak it's made to traditional protein degrading technology can help break down tau, which has long been a focus of Alzheimer’s drug research.biopharma_dive · 7d ago
- Novartis ends BioArctic pact; Two VC firms raise inaugural fundsPlus news about Teva, Ultragenyx and Specific Biologics. Novartis cans BioArctic collab: The Swiss pharma axed its discovery-stage work with the Swedish biotech, which created the Alzheimer’s drug…endpoints · 13d ago
- Novartis puts $772M BioArctic deal on ice, skates away from brain-delivery allianceNovartis is discontinuing a neurodegeneration alliance with BioArctic in which the companies aimed to develop a drug candidate that could cross the blood-brain barrier.biospace · 13d ago
- BioArctic left out in the cold as Novartis walks away from $800M neuro collabJust 14 months after Novartis signed an $800 million biobucks neuroscience partnership with BioArctic, the Swiss pharma has walked away from the deal.fiercebiotech · 14d ago
- Biogen set up for growth even without M&A but CEO won’t rule it outBiogen is growing as planned, with marketed products generating more revenue and multiple late-stage readouts expected over the next year. Building out an early-stage pipeline would be a bonus, CEO…biospace · 19d ago
- Biogen notches 3rd straight quarter of growth thanks to newer products, ApellisGrowth portfolio products like Leqembi and Spinraza helped drive Biogen to $2.8 billion in revenue for the third quarter.biospace · 20d ago
- Experimental Arrowhead RNAi drug hints at Alzheimer’s benefitIn a first, a subcutaneously administered RNA interference medicine crossed into the brain and plummeted levels of a protein implicated in the disease.biopharma_dive · 1mo ago
- Chutes & Ladders—Vir looks to Liu to lead late-stage pushAs Vir pushes its lead hepatitis D combo through phase 3 development, the biotech has tapped an experienced medical expert to light the way. David Liu, M.D., Ph.D., is now Vir’s chief medical offic…fiercebiotech · 1mo ago
Data sources
last refreshed 31m ago
Found something off?
comments(0)
5-min edit window · permanent after that